Net Monetary Benefit

Net monetary benefit

Net monetary benefit (NMB) expresses the value of a healthcare option on a monetary scale by valuing its expected health outcomes at a stated cost-effectiveness threshold and subtracting its expected costs. It provides an alternative to ratio-based cost-effectiveness measures and is particularly useful when several options, uncertainty or statistical analysis need to be considered.

NMB is threshold-dependent. Changing the cost-effectiveness threshold changes the monetary value assigned to health outcomes and can therefore change which option has the highest net benefit.

How net monetary benefit is calculated

For healthcare option j:

NMBⱼ = (λ × Eⱼ) − Cⱼ

where:

• λ is the stated cost-effectiveness threshold per unit of health outcome;
• Eⱼ is the expected health outcome for option j; and
• Cⱼ is the expected cost of option j.

When health outcomes are measured in QALYs and λ is expressed as cost per QALY, multiplying health by λ places expected health and expected cost on the same monetary scale.

NMB should be calculated using costs and outcomes that refer to the same population, perspective, comparator set, time horizon, price basis and analytical assumptions.

Net monetary benefit and incremental net monetary benefit

Net monetary benefit and incremental net monetary benefit are related but distinct quantities.

NMB is calculated separately for each option:

NMBⱼ = (λ × Eⱼ) − Cⱼ

Incremental net monetary benefit (INMB) compares two options:

INMB = NMBnew − NMBcomparator

which is equivalent to:

INMB = (λ × ΔE) − ΔC

A positive INMB means the new option has greater net monetary benefit than the comparator at the stated threshold. A negative INMB means the comparator has greater net monetary benefit.

The distinction matters when several alternatives are evaluated because each option can be assigned its own NMB and the alternatives can then be ranked directly.

How NMB is used with several alternatives

When several mutually exclusive healthcare options are available, calculate expected NMB for every feasible option using the same threshold and analytical assumptions.

The option with the highest expected NMB is favoured on cost-effectiveness grounds at that threshold.

This approach avoids interpreting a collection of isolated pairwise ICERs against a common baseline. The comparison should still include all relevant alternatives and respect the decision problem, evidence and analytical assumptions.

The highest-NMB option is not automatically the option that should be adopted. Affordability, equity, feasibility, implementation, evidence quality and other institutional considerations may affect the final decision.

Relationship between NMB and the ICER

For a two-option comparison in which the new intervention is more costly and more effective, the conventional ICER decision rule can be rearranged into an incremental net-benefit rule.

If:

ICER = ΔC ÷ ΔE

then the intervention is favoured on cost-effectiveness grounds at threshold λ when:

(λ × ΔE) − ΔC > 0

or:

INMB > 0

The two approaches therefore produce equivalent rankings when the ratio is meaningful and the same threshold and analytical assumptions are used.

Net benefit has an important advantage because it remains interpretable when ratio-based ICERs become awkward or ambiguous, including situations involving negative ICERs or incremental effects close to zero.

How the cost-effectiveness threshold affects NMB

The threshold determines the monetary value assigned to one additional unit of health.

A higher threshold increases the monetary value placed on health outcomes and therefore increases the NMB of options producing more health, all else equal.

A lower threshold places less monetary value on those additional outcomes.

The threshold should be stated with its:

• value;
• currency;
• price year;
• health-outcome unit;
• jurisdiction or decision context;
• source; and
• institutional interpretation.

A threshold should not automatically be described as willingness to pay. Depending on the decision framework, it may represent a demand-side valuation, a supply-side opportunity-cost estimate, an institutional benchmark or another decision rule.

Worked example

Consider two options evaluated using a threshold of £20,000 per QALY.

Current care

• Expected cost: £10,000
• Expected QALYs: 4.50

NMB = (£20,000 × 4.50) − £10,000 = £80,000

New intervention

• Expected cost: £14,000
• Expected QALYs: 4.80

NMB = (£20,000 × 4.80) − £14,000 = £82,000

The new intervention has the higher NMB.

The same result can be expressed incrementally:

ΔC = £4,000

ΔE = 0.30 QALYs

INMB = (£20,000 × 0.30) − £4,000 = £2,000

The positive INMB confirms that the new intervention has £2,000 greater net monetary benefit per patient at the stated threshold.

NMB and uncertainty

Economic evaluation rarely produces costs and outcomes with certainty. NMB is especially useful for uncertainty analysis because it transforms costs and outcomes into a single linear quantity at each threshold.

In probabilistic sensitivity analysis, NMB can be calculated for every option in every simulation.

For simulation s and option j:

NMBⱼ,s = (λ × Eⱼ,s) − Cⱼ,s

The option with the highest NMB in each simulation can then be identified.

Across simulations, analysts can estimate:

• expected NMB for each option;
• expected incremental NMB;
• the probability that each option is cost-effective at a stated threshold;
• cost-effectiveness acceptability curves; and
• quantities used in value-of-information analysis.

Probability of cost-effectiveness and expected NMB answer different questions. The option with the greatest probability of being cost-effective is not necessarily the option with the greatest expected NMB.

Expected net monetary benefit

When costs and outcomes are uncertain, decision-making should generally compare the expected NMB of the available options.

For option j:

Expected NMBⱼ = E[(λ × Eⱼ) − Cⱼ]

The option with the highest expected NMB is favoured on expected cost-effectiveness grounds at the stated threshold.

Expected NMB preserves the magnitude of possible gains and losses. This distinguishes it from a probability-based measure that records only how often an option has the highest net benefit.

NMB and dominance

NMB provides a consistent monetary-scale comparison across alternatives, but analysts should still understand the underlying cost and outcome differences.

An option that is less costly and more effective than another strictly dominates it. Its economic advantage should not be obscured by reporting only a net-benefit number.

Likewise, fully incremental analysis remains useful for understanding the efficient set of alternatives and extended dominance.

NMB complements these methods rather than removing the need to understand the underlying cost-effectiveness structure.

NMB does not measure affordability

Positive NMB or the highest NMB does not mean that a healthcare system can afford an intervention.

NMB evaluates comparative value at a stated threshold. Budget impact analysis addresses the financial consequences of adoption for a particular budget holder over a specified period.

An intervention can have the highest expected NMB and still create substantial expenditure pressure.

NMB does not make the final decision

Net monetary benefit summarises costs and health outcomes under a specified threshold and analytical framework. It does not incorporate every consideration relevant to healthcare decisions.

NMB does not by itself determine:

• affordability;
• equity;
• implementation feasibility;
• organisational impact;
• evidence quality;
• distribution of costs and health gains;
• ethical considerations; or
• the final reimbursement or adoption decision.

These considerations may be incorporated separately within health technology assessment or another decision process.

Common mistakes and how to avoid them

• Do not use NMB and INMB as though they are identical quantities.
• Do not calculate option-level NMB using incremental costs and effects.
• Do not describe λ automatically as willingness to pay without checking its institutional interpretation.
• Do not compare NMB values calculated using different thresholds, populations, perspectives, horizons or price bases without adjustment.
• Do not interpret positive INMB as proof of affordability or automatic adoption.
• Do not select the option with the greatest probability of cost-effectiveness when the decision criterion is greatest expected NMB.
• Do not hide dominance or important cost-and-outcome differences behind a single summary statistic.
• Do not report NMB without stating the threshold used.

What should be reported

Report the alternatives, population, perspective, time horizon, costs, outcomes, threshold value and interpretation, currency and price year, discounting, option-level NMB, incremental NMB where relevant, uncertainty methods, expected NMB, probability-based results where used, assumptions, limitations and the distinction between cost-effectiveness and the wider decision.